Publications by authors named "D Maimone"
Article Synopsis
- Late onset multiple sclerosis (LOMS) accounts for 0.6 to 12% of all MS cases, but there's limited information on its incidence in the general population.
- A study in Catania, Italy, identified 183 LOMS patients (with a mean age of onset at 55.8 years), revealing an average annual incidence rate of 2.87 per 100,000 person-years.
- Over time, the incidence rate increased notably, particularly among individuals aged 60-69, suggesting that MS may begin at older ages.
Background And Objectives: Women with multiple sclerosis (MS) are at risk of disease reactivation in the early postpartum period. Ocrelizumab (OCR) is an anti-CD20 therapy highly effective at reducing MS disease activity. Data remain limited regarding use of disease-modifying therapies (DMTs), including OCR, and disease activity during peripregnancy periods.
View Article and Find Full Text PDFArticle Synopsis
- - The study examines the effectiveness of high-efficacy disease-modifying treatments (hDMTs) versus low-efficacy treatments (lDMTs) in reducing spinal cord lesions in multiple sclerosis (MS) patients, noting the limited previous data on this specific outcome.
- - Researchers analyzed data from patients with relapse-onset MS who underwent MRI scans before and after starting treatment, comparing new lesions in both cord and brain areas.
- - Results indicate that while hDMTs significantly reduced new brain lesions and MS relapses compared to lDMTs, they did not show a significant benefit in preventing new spinal cord lesions.
Patient-reported outcomes (PROs) are essential for understanding the effects of MS and its treatments on patients' lives; they play an important role in multiple sclerosis (MS) research and practice. We present the protocol for an observational study to prospectively assess the effect of cladribine tablets on PROs and their correlation to disability and physical activity in adults with highly active relapsing MS switching from a first disease modifying drug (DMD) to cladribine tablets in routine clinical practice at study sites in Italy. The primary objective will be to evaluate changes from baseline in the impact of highly active MS on self-assessed physical functioning 52 weeks after the switch to cladribine tablets using the Multiple Sclerosis Impact Scale-29 (MSIS-29).
View Article and Find Full Text PDF